New strategies for the treatment of secondary hyperparathyroidism

Tadao Akizawa, Kazuhiro Shiizaki, Ikuji Hatamura, Motohiro Kamimura, Masahide Mizobuchi, Nobuhiko Narukawa, Shinji Sumikado, Toshibumi Sakaguchi, Shigeo Negi, Hiroaki Ogata, Eriko Kinugasa

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Classic pathogeneses of secondary hyperparathyroidism (2HPT), hyperphosphatemia, vitamin D deficiency, and hypocalcemia, have been treated by the administration of phosphorus binders and vitamin D derivatives. However, these therapies have not brought about a successful result. The main reason could be attributed to hypercalcemia resulting from the administration of calcium salts as a phosphorus binder and the calcemic action of vitamin D. To prevent hypercalcemia, non-calcium-containing phosphorus binders and vitamin D analogues, which suppress parathyroid hormone (PTH) secretion with minimum calcemic action, have been developed. Furthermore, calcimimetics that stimulate the calcium-sensing receptor of parathyroid cells and suppress PTH secretion are now under clinical trial. Direct injection therapy of vitamin D analogues or calcimimetics into the parathyroid gland also has been reported. These new strategies are expected to effectively and safely suppress 2HPT, which has been resistant to conventional medical treatments.

Original languageEnglish (US)
Pages (from-to)S100-S103
JournalAmerican Journal of Kidney Diseases
Issue number3 SUPPL. 1
StatePublished - Mar 1 2003


  • Calcimimetics
  • Chronic renal failure (CRF)
  • Maxacalcitol
  • Percutaneous calcitriol analogue injection
  • Phosphorus binder
  • Secondary hyperparathyroidism (2HPT)
  • Vitamin D analogue

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'New strategies for the treatment of secondary hyperparathyroidism'. Together they form a unique fingerprint.

Cite this